Abvc Biopharma, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
ABVC BioPharma, Inc. announces its 2026 Annual Meeting of Shareholders to vote on director re-elections, auditor ratification, and an increase in its equity incentive plan, while facing a 'going concern' warning.
NASDAQ
ABVC BioPharma is holding its 2025 annual shareholder meeting to vote on key proposals including director re-election, auditor ratification, land purchase authorization, and an equity incentive plan amendment.
NASDAQ
ABVC BioPharma updates its proxy statement to include shares from a recent private transaction with Lind and clarifies quorum requirements for its upcoming annual meeting.
NASDAQ
ABVC BioPharma is seeking stockholder approval to issue shares related to convertible notes and warrants issued to Lind Global Fund II, LP, to comply with Nasdaq listing rules, as part of a financing transaction to address the company's cash needs.